Skip to main content
OpenTrials
Completed

NCT Number: NCT04960631

Evaluation of Clinical Significance and Feasibility of CT Guided Biopsy of Double Site Lesions：A Preliminary Lung Centered Study

This study aims to explore the clinical significance and feasibility of double site biopsy by analyzing the pathological characteristics and the incidence of main complications of CT guided puncture biopsy of lung and other parts coexisting lesions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma of the Lungs

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University Third Hospital

Beijing, Beijing Municipality, 010, China

About this study

CT guided biopsy is minimally invasive, accurate and low cost. It is often used as an important diagnostic method when the clinical suspect of malignant disease or the treatment effect of the disease is not good. In patients with suspected malignant lung disease, metastasis of other parts of lung, pulmonary door, mediastinum, bone, and distant soft tissue may be combined at the same time. It is the key link of clinical work to evaluate the nature of these coexisting lesions accurately and choose appropriate treatment methods. At present, there is little clinical study on lung centered double site biopsy. This study aims to explore the clinical significance and feasibility of double site biopsy by analyzing the pathological characteristics and the incidence of main complications of CT guided puncture biopsy of lung and other parts coexisting lesions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with suspected malignancy
  • underwent dual site CT guided biopsy in the Third Hospital of Peking University

Exclusion criteria

-

Treatment and study plan

Double site CT guided needle biopsy

Diagnostic Test

Double site CT guided needle biopsy

Primary outcomes

  1. for the combination of two site biopsies

    Time frame: up to 2weeks

    The incidence of 4 kinds of combined pathological results in different lesion location groups was analyzed.

  2. for the combination of two site biopsy approaches 1

    Time frame: up to 2weeks

    The incidence of pneumothorax on the surgical side after unilateral lung biopsy

  3. for the combination of two site biopsy approaches 2

    Time frame: up to 2weeks

    the incidence of pneumothorax on the surgical side after bilateral lung biopsy

  4. for the combination of two site biopsy approaches 3

    Time frame: up to 2weeks

    the incidence of intra tissue hemorrhage after biopsy were statistically analyzed.

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jul 14, 2021
Registry last updated
Jul 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.